Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ESRRA | P11474 | 3/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595513 | 0.85 | ALDH1A1 (0.59) | ALDH1A1MAPTPOLBALOX15NR1I2 | |
| SCHEMBL27396817 | 0.85 | GPR3 (0.44) | ALDH1A1MAPTPOLBHTTKDM4E | |
| SCHEMBL370445 | 0.81 | ESR1 (0.45) | MAPTWDR5 | |
| SCHEMBL13141415 | 0.81 | GPR3 (0.44) | ALDH1A1MAPTALOX15LMNACYP2C9 | |
| SCHEMBL7204289 | 0.80 | ESRRA (0.72) | ALDH1A1MAPTPOLBALOX15NR1I2 | |
| SCHEMBL28440086 | 0.79 | ALDH1A1 (0.57) | ALDH1A1MAPTPOLBALOX15NR1I2 | |
| SCHEMBL25589644 | 0.79 | GPR3 (0.43) | MAPTALOX15LMNACYP2C9HSD17B10 | |
| SCHEMBL10064799 | 0.79 | GPR3 (0.44) | MAPTPOLB | |
| SCHEMBL17688872 | 0.79 | GPR3 (0.44) | MAPTALOX15LMNACYP2C9HSD17B10 | |
| SCHEMBL13439935 | 0.79 | GPR3 (0.44) | ALOX15LMNACYP2C9HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-04-01 | — | — | US | disclosed |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9416132-B2 | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM2, PIM1, PIM3 | ALDH1A1 2430/4885MAPT 2610/4885POLB 1602/4885 |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 1698/4885MAPT 4110/4885POLB 1882/4885 |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 3433/4885MAPT 611/4885POLB 2922/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 3433/4885MAPT 611/4885POLB 2922/4885 |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 3601/4885MAPT 764/4885POLB 3728/4885 |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM1, PIM2, PIM3 | ALDH1A1 3557/4885MAPT 727/4885POLB 2699/4885 |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 1612/4885MAPT 4202/4885POLB 1865/4885 |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 3433/4885MAPT 611/4885POLB 2922/4885 |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | ALDH1A1 4345/4885MAPT 2051/4885POLB 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.